Medication info
Excrebac 5/80/10 mg Tablets

Excrebac 5/80/10 mg Tablets

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.94mg / 1 tabletValsartan›80mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
HanKook Hyutecs Pharmaceutical Co., Ltd.
Appearance
Pink egg-shaped film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202106227 · Approved 2021.08.27 · Insurance code 649105370

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water. If possible, it is recommended that this medicine be taken at the same time each day (e.g., before breakfast). This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate medicines may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before starting the amlodipine/valsartan combination, it is recommended that the dose of each individual component (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater), but the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or to patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. The amlodipine/valsartan combination should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted for maintenance therapy. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
HanKook Hyutecs Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This drug is used in patients with essential hypertension whose blood pressure is not adequately controlled, even when treated with a combination of amlodipine and valsartan, and is applicable only when rosuvastatin is also required. The amlodipine/valsartan combination is used for the treatment of essential hypertension and helps effectively lower blood pressure. Rosuvastatin is used as an adjunct when dietary changes and exercise alone do not control hypercholesterolemia and dyslipidemia. It is also effective in delaying the progression of atherosclerosis due to hypercholesterolemia and in reducing the risks of cardiovascular diseases such as stroke and myocardial infarction. This drug is used to simultaneously manage blood pressure and lipid abnormalities, thereby improving cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water. If possible, it is recommended that this medicine be taken at the same time each day (e.g., before breakfast). This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate medicines may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before starting the amlodipine/valsartan combination, it is recommended that the dose of each individual component (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater), but the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or to patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. The amlodipine/valsartan combination should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted for maintenance therapy. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This drug can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any of the ingredients in this drug, or those with severe liver or kidney disease, as well as pregnant or breastfeeding women, should not take this drug. Patients who are volume-depleted or have low sodium levels may experience hypotension, so their condition should be thoroughly assessed before taking this drug. If symptoms of hypotension appear, they should lie down and rest immediately and seek proper treatment at a medical facility if necessary. Patients with high potassium levels should be cautious when taking potassium supplements or medications that raise potassium levels along with this drug, and blood potassium concentrations should be monitored frequently. Patients with renal artery stenosis or those who have undergone kidney transplantation may experience worsening kidney function while taking this drug, so it should be taken carefully under a physician's guidance. Patients with heart failure, those recovering from myocardial infarction, or patients with heart valve disease should be monitored closely while taking this drug. If muscle pain, weakness, or cramps occur during treatment, patients should notify healthcare personnel immediately and undergo examination; if severe, the medication may need to be discontinued. Dizziness or fatigue may occur during driving or operating machinery, so caution is advised. This drug may interact with specific medications, so it is essential to notify the physician or pharmacist if taking other medications. Pregnant or breastfeeding women should not take this drug, and if planning a pregnancy, appropriate contraceptive methods should be used. This drug is not recommended for children under 18 as safety and efficacy have not been established. Elderly patients may have increased sensitivity to the medication, so starting with lower doses and gradually increasing is recommended. Routine liver function tests and muscle-related monitoring should be performed during treatment, and if any unusual symptoms arise, healthcare personnel should be consulted immediately. In cases of overdose, there is a risk of severe hypotension, shock, etc., so immediate emergency treatment is required, and self-treatment should be avoided.

Side effects

Peripheral edema, heat sensation, increased ALT, increased AST, increased blood creatinine, flank pain, neck pain, dizziness, sensory loss, rhinitis, rash, nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, drowsiness, orthostatic dizziness, abnormal sensation, vertigo, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, dry mouth, erythema, sweating, rash, itching, joint swelling, back pain, arthritis, muscle cramps, lethargy, polyuria, nocturia, erectile dysfunction, edema, eyelid edema, facial edema, fatigue, flushing, asthenia, facial flushing, chest pain, pain, enuresis, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, hypercholesterolemia, hypoglycemia, headache, dizziness, itching, peripheral edema, hypotension, edema, chest pain, pain, cough, enuresis, chest pain, weight gain, arthralgia, skeletal pain, rhabdomyolysis, gingival hyperplasia, gastritis, neuralgia, sensory loss, Stevens-Johnson syndrome, angioedema, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremors, taste disturbance, peripheral neuropathy, hypertonia, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gingival enlargement, hepatitis, jaundice, alopecia, purpura, skin discoloration, photosensitivity reaction, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, urinary dysfunction, enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, elevated liver function tests, serum sickness, elevated serum potassium, vasculitis, angioedema, bullous dermatitis, myalgia, renal failure, renal injury, elevated serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory infection, viral infection, mesenteric edema, headache, dizziness, constipation, nausea, abdominal pain, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptom-associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, headache, dizziness, increased ALT, chest pain, cough, myalgia, increased CK, constipation, increased AST, asthenia, arthralgia, fatigue, numbness, abnormal sensation, chest discomfort, nausea, abdominal pain, diarrhea, anorexia, abdominal distension, itching, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, increased blood creatinine, chest pain, weight gain, arthralgia, skeletal pain, rhabdomyolysis, gingival hyperplasia, gastritis, neuralgia, sensory loss, Stevens-Johnson syndrome, angioedema

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container as it may be sensitive to air or moisture. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius. This ensures the drug's effectiveness is preserved for a long time.

Appearance and packaging

Appearance

Pink egg-shaped film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.